Recently, it has been reported that the trial did not meet its primary endpoint of investigator-assessed PFS for patients treated with the investigational triplet therapy, although an important trend was seen in favor of the triple therapy arm.
← all excerpts
Immune Checkpoint Inhibitors and RAS-ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma.
1
—
—